Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in recurrent or refractory DLBCL
NCT05192486Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emfizatamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 3 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
emfizatamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05192486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192486.